Following Richmond Pharmacology�s Chief Executive Officer and Principal Investigator Dr Jorg Taubel�s presentation at the recent 2nd DIA Cardiac Safety Workshop in Japan, further data will be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), taking place 1st to 3rd December 2011, at Act City Hamamatsu.This year�s annual scientific meeting will assess the latest trends in clinical pharmacology and, as a first, will be jointly hosted by the three societies of the Japanese Society of Clinical Pharmacology and Therapeutics (JPCPT), the Korean Society of Clinical Pharmacology and Therapeutics (KSCPT) and the American Society of Clinical Pharmacology and Therapeutics (ASCPT).Dr Taubel�s poster presentation session will provide an update on the original research carried out by Richmond Pharmacology, and is scheduled for Thursday, 1st December between 14:15 and 15:10:

  • Alternative Methods for the Confirmation of Assay Sensitivity in Thorough QT Studies (Program number: 1-P-77)
  • QT Prolongation in Healthy Japanese Subjects Receiving Moxifloxacin in Thorough QT Studies (Program number: 1-P-78)
  • Sex Differences of the Effect of Moxifloxacin  - A Meta -analysis of Five thorough QT Studies (Program number:  1-P-79)

Our total success rate in all Thorough QT studies reported to date confirms that we are a leading research unit for cardiac safety studies - either as a one stop solution or in conjunction with our preferred partner core labs.For further information on our cardiac safety expertise and other specialist services please speak to a company representative at booth number 5, where we will be available to discuss how Richmond can benefit your prospective Phase I/II study requirements.We look forward to seeing you in Tokyo.

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event